Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.55 Million SEK | -42.69% |
| 2022 | 16.67 Million SEK | 13.4% |
| 2021 | 14.7 Million SEK | 27.75% |
| 2020 | 11.51 Million SEK | -25.49% |
| 2019 | 15.44 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.94 Million SEK | -16.89% |
| 2024 Q2 | 6.05 Million SEK | -23.77% |
| 2023 Q1 | 14.84 Million SEK | -10.96% |
| 2023 Q3 | 11.47 Million SEK | -13.89% |
| 2023 FY | 9.55 Million SEK | -42.69% |
| 2023 Q4 | 9.55 Million SEK | -16.74% |
| 2023 Q2 | 13.33 Million SEK | -10.22% |
| 2022 Q2 | 16.52 Million SEK | -9.64% |
| 2022 FY | 16.67 Million SEK | 13.4% |
| 2022 Q1 | 18.28 Million SEK | 24.37% |
| 2022 Q4 | 16.67 Million SEK | 12.09% |
| 2022 Q3 | 14.87 Million SEK | -9.97% |
| 2021 Q1 | 9.91 Million SEK | -13.84% |
| 2021 Q4 | 14.7 Million SEK | -14.71% |
| 2021 FY | 14.7 Million SEK | 27.75% |
| 2021 Q3 | 17.24 Million SEK | 83.21% |
| 2021 Q2 | 9.41 Million SEK | -5.11% |
| 2020 Q1 | 14.15 Million SEK | -8.35% |
| 2020 FY | 11.51 Million SEK | -25.49% |
| 2020 Q4 | 11.51 Million SEK | -0.86% |
| 2020 Q3 | 11.61 Million SEK | -9.7% |
| 2020 Q2 | 12.85 Million SEK | -9.19% |
| 2019 Q3 | 16.72 Million SEK | -7.05% |
| 2019 Q2 | 17.99 Million SEK | -6.54% |
| 2019 Q1 | 19.25 Million SEK | 0.0% |
| 2019 FY | 15.44 Million SEK | 0.0% |
| 2019 Q4 | 15.44 Million SEK | -7.65% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.408% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.408% |
| Arcoma AB | 3.87 Million SEK | -146.76% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 95.9% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.484% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 94.246% |
| CellaVision AB (publ) | 64.7 Million SEK | 85.229% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -2005.066% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -430.944% |
| Duearity AB (publ) | 10.58 Million SEK | 9.686% |
| Dignitana AB (publ) | 19.1 Million SEK | 49.974% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -83.788% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.882% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -15.848% |
| Iconovo AB (publ) | 7.72 Million SEK | -23.717% |
| Integrum AB (publ) | 6.42 Million SEK | -48.766% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -4538.78% |
| OssDsign AB (publ) | 3.15 Million SEK | -203.397% |
| Paxman AB (publ) | 13.57 Million SEK | 29.573% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 53.9% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -40.606% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 69.935% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -121.946% |
| Senzime AB (publ) | 11.46 Million SEK | 16.664% |
| SpectraCure AB (publ) | 6.71 Million SEK | -42.281% |
| Stille AB | 62.94 Million SEK | 84.816% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.543% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 69.6% |